Claire de Oliveira1, Karen E Bremner2, Reka Pataky3, Nadia Gunraj4, Mahbubul Haq4, Kelvin Chan5, Winson Y Cheung6, Jeffrey S Hoch7, Stuart Peacock8, Murray D Krahn9. 1. Centre for Addiction and Mental Health, Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ont. 2. University Health Network, Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ont. 3. Canadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, Vancouver, BC. 4. Institute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, Ont. 5. Department of Medicine, University of Toronto, Sunnybrook Health Sciences Centre and Princess Margaret Hospital, Toronto, Ont. 6. British Columbia Cancer Agency, University of British Columbia, Vancouver, BC. 7. Canadian Centre for Applied Research in Cancer Control, St. Michael's Hospital, Cancer Care Ontario, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ont. 8. Canadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, School of Population and Public Health, University of British Columbia, Vancouver, BC. 9. Toronto Health Economics and Technology Assessment Collaborative, Department of Medicine and Faculty of Pharmacy, University of Toronto, University Health Network, Toronto, Ont.
Abstract
BACKGROUND: Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs. METHODS: We selected patients aged 19-44 years who had received a diagnosis of melanoma, breast cancer (female only), testicular cancer or thyroid cancer, in addition to patients aged 45 years and older who had received a diagnosis of breast (female only), prostate, lung or colorectal cancer, between 1997 and 2007. Patients were identified from the Ontario Cancer Registry. Using linked administrative databases, we determined use and costs of chemotherapy, radiotherapy, cancer-related surgery, other admissions to hospital and home care. We adjusted all costs to 2009 Canadian dollars. RESULTS: We identified 20 821 patients aged 19-44 years and 178 797 patients aged 45 years and older. The greatest increases in costs during the study period were for melanoma, breast cancer, colorectal cancer, lung cancer and prostate cancer (p < 0.05). For prostate and lung cancers, mean costs increased 50% (from $11 490 and $22 037 to $15 170 and $34 473, respectively). Mean costs doubled for breast (from $15 460 and $12 909 to $35 977 and $29 362 for younger and older patients, respectively) and colorectal cancers (from $24 769 to $43 964), and nearly tripled for melanoma (from $3581 to $8934). Costs related to hospital admissions accounted for the largest portion of total costs. The use of chemotherapy, radiotherapy and home care generally increased for all cancers. INTERPRETATION: The significant increase in mean costs of initial cancer treatment among the patients included in this study was primarily due to more patients receiving adjuvant therapy and home care, and to the increasing expenditures for these services and cancer-related surgeries. Understanding trends in health care use and costs can help policy-makers to take the necessary measures to achieve a more accountable, high-performing health care system.
BACKGROUND:Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs. METHODS: We selected patients aged 19-44 years who had received a diagnosis of melanoma, breast cancer (female only), testicular cancer or thyroid cancer, in addition to patients aged 45 years and older who had received a diagnosis of breast (female only), prostate, lung or colorectal cancer, between 1997 and 2007. Patients were identified from the Ontario Cancer Registry. Using linked administrative databases, we determined use and costs of chemotherapy, radiotherapy, cancer-related surgery, other admissions to hospital and home care. We adjusted all costs to 2009 Canadian dollars. RESULTS: We identified 20 821 patients aged 19-44 years and 178 797 patients aged 45 years and older. The greatest increases in costs during the study period were for melanoma, breast cancer, colorectal cancer, lung cancer and prostate cancer (p < 0.05). For prostate and lung cancers, mean costs increased 50% (from $11 490 and $22 037 to $15 170 and $34 473, respectively). Mean costs doubled for breast (from $15 460 and $12 909 to $35 977 and $29 362 for younger and older patients, respectively) and colorectal cancers (from $24 769 to $43 964), and nearly tripled for melanoma (from $3581 to $8934). Costs related to hospital admissions accounted for the largest portion of total costs. The use of chemotherapy, radiotherapy and home care generally increased for all cancers. INTERPRETATION: The significant increase in mean costs of initial cancer treatment among the patients included in this study was primarily due to more patients receiving adjuvant therapy and home care, and to the increasing expenditures for these services and cancer-related surgeries. Understanding trends in health care use and costs can help policy-makers to take the necessary measures to achieve a more accountable, high-performing health care system.
Authors: Joan L Warren; Martin L Brown; Michael P Fay; Nicola Schussler; Arnold L Potosky; Gerald F Riley Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Joan L Warren; K Robin Yabroff; Angela Meekins; Marie Topor; Elizabeth B Lamont; Martin L Brown Journal: J Natl Cancer Inst Date: 2008-06-10 Impact factor: 13.506
Authors: Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark Journal: N Engl J Med Date: 2002-10-17 Impact factor: 91.245
Authors: Kathleen Lang; Martin D Marciniak; Doug Faries; Michael Stokes; Don Buesching; Craig Earle; Joseph Treat; Nathalie Morissette; David Thompson Journal: Lung Cancer Date: 2008-07-22 Impact factor: 5.705
Authors: Claire de Oliveira; Karen E Bremner; Reka Pataky; Nadia Gunraj; Kelvin Chan; Stuart Peacock; Murray D Krahn Journal: CMAJ Open Date: 2013-01-16
Authors: Ashley C Mays; Harrison G Bartels; Paul R Wistermayer; Matt L Rohlfing; Christopher M Gentile; Ralph D'Agostino; Joshua D Waltonen Journal: Head Neck Date: 2017-11-13 Impact factor: 3.147
Authors: Claire de Oliveira; Erin M Macdonald; Diane Green; Patricia Colton; Marion Olmsted; Susan Bondy; Paul Kurdyak Journal: CMAJ Open Date: 2016-11-03
Authors: N Mittmann; J M Porter; J Rangrej; S J Seung; N Liu; R Saskin; M C Cheung; N B Leighl; J S Hoch; M Trudeau; W K Evans; K N Dainty; C DeAngelis; C C Earle Journal: Curr Oncol Date: 2014-12 Impact factor: 3.677